CPhI reaches 25,000.
Staged in Frankfurt, Germany, CPhI 2008 passed a key milestone of 25,000 attendees for the first time. With the ICSE contract services and P-MEC pharma machinery and equipment events, the exhibitions form the world's largest pharmaceutical ingredients and services event. Numbering a combined total of more than 1700 exhibitors, the events had an attendance that was 30% up on the city's previous hosting in 2003. New features at the exhibitions included daily, 75-minute Breakfast Briefings on key industry topics and the launch of new digital platforms that extend CPhI into a 24/7 information brand. Of note are CPhI's new gateway website (www. wherepharmameets.com), WPM TV--the news station for the pharmaceutical industry--and the What'sNewInPharma weekly e-newsletter. To mark the increasing focus on biotech as a key driver in pharmaceutical production, BioPh (Bio Solutions for Pharma) was launched to take ICSE's Biotech Zone to the next level. It also provides a focus for the accelerating convergence of pharma and biotech business models in the unrivalled networking space offered by CPhI.
The new ICSE Speakers' Corner was a marked success, with 26 presentations during the event. And, fresh from its successful South American debut in August, P-MEC Europe informed industry professionals about new developments in pharmaceutical manufacturing. The events closed with positive feedback from exhibitors and strong booking levels for 2009. CPhI Event Director, Annemieke Timmers, commented: "Feedback from this edition of CPhI Worldwide has been very strong, with positive comments on the venue and the high quality of visitors and their enquiries." And, she added: "To evolve CPhI into a true 24/7 information service brand, we have been planning the extension into digital for some time. The new digital platforms, including WPM TV and the WNIP e-newsletter will ensure that the brands add daily content value, as well as remaining the annual meeting place for the industry." The information theme is being complemented by the new series of CPhI Conferences. Following the first two in Spring/Summer, five further events are being staged in the UK and Germany before year-end. Next year's twentieth CPhI Worldwide, with ICSE, BioPh and P-MEC, returns to Spain's popular Feria de Madrid, which first hosted the exhibitions in 2005. Dates for the diary are 13-15 October (www.cphi.com, www.icsexpo.com, www.p-mec.com).
Website Revamp for Doyen
Doyen Medipharm, a specialist supplier of medical and pharmaceutical converting and packaging machinery with sites in the UK, USA and Malaysia, has launched its new website. International orientation, increased demand for line automation and innovative product developments made a new marketing strategy and material necessary, the company claims, adding that the new website is only the starting point for a variety of updates to its corporate design. Taking a fresh approach to the familiar corporate colours of grey, green and white, the familiar view of the D-Plus will remain. User friendliness is the key to the new website; the navigation is easy to follow and animation illustrates the principles of Doyen's technology. The site provides case studies and spec sheet downloads in the Solutions section, as well as information on recent developments and trade shows. The popular customized spares ordering system--with regularly updated prices and recommended spares--has been redesigned and offers customers a higher degree of confidentiality and access to up-to-date service charges. For further information, visit www.doyenmedipharm.com.
Excelsyn Organizes for Strong Growth
Pharma and biotech manufacturing services group, Excelsyn, has announced a series of moves reflecting 2 years of significant business growth--especially from customers in Asia and the USA. With more projects transitioning from lab to pilot plant scale, the company has refocused its chemistry teams, which already offer "24/7" service. With an eye to increasing customer focus and continuing growth, there have been a number of important organizational changes. Mark Chadwick has taken full commercial responsibility as VP Business Development, reporting directly to CEO Ian Shott. To underpin delivery performance, a series of new appointments under COO David Rowles have also been made. They include Gareth Jenkins moving to the newly created position of VP Research and Development, together with Dave Parry taking over the New Product Introduction team.
Capabilities at the Holywell (North Wales) facility have recently been strengthened by the addition of Fauske adiabatic and TSU calorimetry equipment, enabling the company to conduct stability testing in-house. It has also added laboratory hydrogenation capability with a bench scale 120 bar autoclave and a 3 L/5 bar autoclave. Excelsyn has also recently completed the initial phase of a 3-year expansion and upgrade programme at Holywell. Under the new site masterplan, major enhancements will include a new API finishing suite, reactor train alignment and increased product isolation capacity. During 2007, Excelsyn received a combined $10 million investment from the private equity and buyout fund, Endless LLP and North Star Equity Investors Ltd. The company was also named 2007 Welsh Exporter of the Year (www.excelsyn.com).
BASF Catalysts Introduces New Pharma Solutions
BASF Catalysts have introduced the first two catalysts from its new NanoSelect platform technology, NanoSelect LF 100 and NanoSelect LF 200, for use in fine chemical and pharmaceutical applications. The two catalysts were specifically designed to meet the market requirements of providing a lead-free replacement for Lindlar catalysts, which have long been used in hydrogenation processes. NanoSelect LF 100 and LF 200 are characterized by supported, well-defined, unimodal nano-sized palladium clusters and show similar activity and selectivity as Lindlar catalysts in selective hydrogenation reactions. "BASF NanoSelect LF 100 and LF 200 catalysts are an environmentally friendly alternative for Lindlar catalysts," says Dr Hans Donkervoort, Global Product Technology Manager Specialty and Fine Chemicals Catalysts at BASF's Catalyst Division. "They additionally offer significant cost savings by having a markedly lower precious metal content." In addition to catalysts, BASF also offers ingredients and custom synthesis services for better drugs, high-end intermediates for the pharmaceutical industry as well as innovative inorganic specialties. For more information, visit www.catalysts.basf.com.
Piramal Launches CTS Services
In the first in a series of business developments since its rebranding in March, Piramal Healthcare has extended its portfolio of early phase drug product development and manufacturing services to embrace clinical trial supplies packaging and distribution. The initiative, focused for global customers, is being launched from the Morpeth UK site of Piramal's Pharma Solutions contract manufacturing business. Morpeth is a fully integrated API, formulation and small-scale manufacturing facility with major logistics capabilities. Acquired from Pfizer in 2006, the site has a global track record in product launch and commercial supply. The newly equipped, 13,000 sq ft clinical trials packaging and distribution facility has the capability for primary packaging solid dosage forms--including multidose blistering and walleting. Secondary packaging booths are set up for the labelling and assembly of various dosage forms. Further flexibility exists within the current footprint for future doubling of primary and secondary packaging capacity.
Piramal offers a full range of CTS services from this new initiative, including comparator drug procurement, label design and printing, solid dose primary packaging, assembly and labelling, product blinding, global storage and distribution and drug destruction. The company also has preferential relationships in-house with CROs based in Romania and India and can provide ready access to customers to these clinical trial centres. Dr R. Ananthanarayanan, President, API and Formulations for the Pharma Solutions business unit, commented: "This expansion into clinical trial supplies adds to our significant existing capabilities in clinical trials manufacturing, integrated either side of the supply chain with formulations development and CROs within the Piramal group. It can dramatically increase flexibility and reduce time to clinic for customers." Ian Morgan, who recently joined from Fisher Clinical Services to head the CTS initiative, added: "Morpeth is a flagship site, where we can build on its deep experience in customer service. Alongside drug product development and clinical trials manufacture, Morpeth offers customers connected capabilities with benefits in time, cost and reduced customer intervention."
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||CPhI review; pharmaceutical products exhibition|
|Article Type:||Conference news|
|Date:||Nov 1, 2008|
|Previous Article:||The European Outsourcing Awards 2008: an innovation showcase for outsourcing.|
|Next Article:||Protein characterization: Katja Aschermann and Andreas Wattenberg, Protagen AG, review the characterization and analysis of proteins for GMP...|